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BACKGROUND: The incidence of human papillomavirus-associated vulval neoplasia is increasing worldwide; yet the associated genetic
changes remain poorly understood.
METHODS: We have used single-nucleotide polymorphism microarray analysis to perform the first high-resolution investigation of
genome-wide allelic imbalance in vulval neoplasia. Our sample series comprised 21 high-grade vulval intraepithelial neoplasia and 6
vulval squamous cell carcinomas, with paired non-lesional samples used to adjust for normal copy number variation.
RESULTS: Overall the most common recurrent aberrations were gains at 1p and 20, with the most frequent deletions observed at 2q, 3p and
10. Copy-neutral loss of heterozygosity at 6p was a recurrent event in vulval intraepithelial neoplasia. The pattern of genetic alterations
differed from the characteristic changes we previously identified in cutaneous squamous cell carcinomas. Vulval neoplasia samples did not
exhibit gain at 5p, a frequent recurrent aberration in a series of cervical tumours analysed elsewhere using an identical protocol.
CONCLUSION: This series of 27 vulval samples comprises the largest systematic genome-wide analysis of vulval neoplasia performed to date.
Despite shared papillomavirus status and regional proximity, our data suggest that the frequency of certain genetic alterations may differ in
vulval and cervical tumours.
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Vulval squamous cell carcinoma (VSCC) is a relatively uncommon
malignancy in women, accounting for less than 5% of gynaeco-
logical cancer (Landis et al, 1999). It is now established that there
are two distinct types of VSCCs, those associated with high-risk a
human papillomavirus (hrHPV) and non-hrHPV-associated var-
iants (McCluggage, 2009). HPV-positive tumours are frequently
contiguous with classic vulval intraepithelial neoplasia (VIN) and
usually arise in younger women. The incidence of HPV-positive
VIN and VSCC is steadily increasing worldwide (Joura et al, 2000).
An association has been reported (Hording et al, 1996; de Bie et al,
2009) between the development of classic VIN/VSCC and cervical
intraepithelial neoplasia (CIN)/cervical SCC (CxSCC) but little is
known of whether, in addition to their positive HPV status and
regional proximity, these lesions share genetic similarities.
Limited data are available on the genetic alterations associated
with VSCC and VIN precursor lesions; previous studies have
used microsatellite marker analysis and metaphase comparative
genomic hybridisation (CGH) rather than higher resolution array-
based techniques (Pinto et al, 1999; Jee et al, 2001; Rosenthal et al,
2001; Allen et al, 2002; Micci et al, 2003; Bryndorf et al, 2004;
Huang et al, 2005). In contrast, the genetic changes associated with
CIN and CxSCC have been extensively studied, most recently using
array-based methods (Hidalgo et al, 2005; Wilting et al, 2006, 2009;
Choi et al, 2007; Kloth et al, 2007; Scotto et al, 2008a, b).
Microarray-based single-nucleotide polymorphism (SNP) analysis
facilitates the accurate and rapid identification of genome-wide allelic
changes in tumour DNA samples. It has been used to investigate the
molecular pathogenesis of various human cancers, including
cutaneous SCC (Purdie et al, 2007, 2009) and cervical cancer (Kloth
et al, 2007; Scotto et al, 2008a, b). Here, for the first time, we have
applied high-resolution microarray analysis to vulval squamous
neoplasia to compare the pattern of genetic changes occurring during
the development of hrHPV-associated VSCC with those alterations
previously identified during cervical carcinogenesis. This reported
investigation of 27 VIN and VSCC samples is the largest systematic
genome-wide analysis of vulval cancer performed to date.
MATERIALS AND METHODS
Study patients
Patients attending a dedicated vulval clinic provided written,
informed consent to undergo a diagnostic or therapeutic biopsy
for either VIN or VSCC. Additional written consent was obtained
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for two 4-mm punch biopsies to be taken, one from the lesion and
one from upper inner arm skin. Full demographic information
was collected through a detailed questionnaire. Ethical approval
for this investigation was obtained from the East London and
City Health Authority local ethics committee and the study was
conducted according to the Declaration of Helsinki Principles. All
patients biopsied have remained under consultant dermato-
logist care (KG). Average duration of follow-up is 5 years (range
2–7 years).
Samples
Routine histopathological evaluation was performed on formalin-
fixed vulval lesional sections stained with hematoxylin and eosin,
with only samples identified as classic VIN or classic VIN-
associated SCC selected for inclusion in this study. Staging of SCC
was performed according to Federation of Gynaecology and
Obstetrics and American Joint Committee on Cancer TNM criteria,
in which Stage I/II is defined as carcinoma confined to the vulva
and perineum, whereas Stage III/IV tumours are those that have
spread to another anogenital region and/or regional lymph
node(s). All diagnoses were confirmed by a single experienced
gynaecological pathologist (NS). All punch biopsies collected were
immediately snap-frozen in liquid nitrogen.
Microdissection and DNA extraction
Lesional tissue was microdissected to overcome the problem of
stromal/lymphocyte contamination that can lead to a reduction in
tumour DNA purity. Laser capture microdissection was performed
using the PALM Microbeam system (Carl Zeiss, Welwyn Garden
City, Hertfordshire, UK) on 8 mm fresh snap-frozen tissue sections
cut onto Zeiss 1.0 PEN membrane slides (Carl Zeiss). DNA was
extracted from lesional and non-lesional control skin biopsies
using the Qiagen DNA Micro Kit (Qiagen, Crawley, West Sussex,
UK) according to the manufacturer’s instructions.
HPV detection and genotyping
The presence of hrHPV DNA was investigated in vulval samples
using the digene Reverse Hybridisation Assay (Qiagen) that detects
18 high-risk mucosotropic HPV types. This study focused on HPV-
associated vulval neoplasia, hence only hrHPV-positive samples
were selected for inclusion in this study.
SNP array analysis
Samples were subjected to 250K Nsp SNP array analysis
(Affymetrix, Santa Clara, CA, USA) and the proprietary Genome
Oriented Laboratory File (GOLF) system was used for the analysis
and display of SNP call and signal data as previously described
(Purdie et al, 2007).
Comparison with cervical cancer data
250K Nsp SNP array data from a previously published study on
cervical carcinomas (Scotto et al, 2008b) were downloaded from
the NCBI GEO database (Edgar et al, 2002; GEO accession
GSE10092) and analysed by GOLF software. This study was chosen
for comparative purposes because the experimental protocol
mirrored the current investigation, both in terms of the use of
fresh frozen samples and the array-based technique. Furthermore,
detailed clinical and histological information, including tumour
stage, were available for the samples. Data from paired non-
lesional samples were not available for analysis, hence raw data
from seven normal cervical epithelial samples analysed by Scotto
et al (2008b) were combined to make a pooled normal control.
Vulval squamous cell carcinoma samples were reanalysed similarly
and the results compared with those from paired sample analysis
to confirm that this approach permitted the accurate identification
of gross chromosomal aberrations.
Statistical analysis
The two-sided Fisher’s exact test was used to calculate P-values,
which were adjusted for multiple testing using Hochberg’s method
(Hochberg, 1988).
RESULTS
Majority of HPV-positive vulval lesions contained HPV-16
The presence of hrHPV DNA was detected in 27 vulval lesional
samples, comprising 21 classic high-grade VIN (VIN2/3) and 6
VIN-associated VSCC (all Stage IA/B). HPV-16 was the most
frequent type, identified in 90% (19 out of 21) VIN samples as well
as in 33% (2 out of 6) VSCC samples (Supplementary Table 1).
HPV-33 was detected in three samples (two VIN, one VSCC) and
HPV-18 was identified in one VSCC lesion. Lesions were associated
with a single HPV type with the exception of 2 multiply-infected
VSCC that contained HPV types 45 and 56 and types 39, 58, 59 and
66, respectively. Two high-grade VIN samples tested negative for
HPV DNA and were excluded from further analysis.
Gain events were the most frequent recurrent
chromosomal aberrations
SNP microarray analysis was performed on lesional and paired
non-lesional DNA samples to adjust for normal copy number
variation (Redon et al, 2006). In high-grade VIN, gains at
chromosomes 1p, 19 and 20 were the most frequent recurrent
events, occurring in a majority of samples (13 out of 21, 62% for 1p
and 19 and 14 out of 21, 67% for 20; Table 1, Figure 1). Some
recurrent losses were observed, with the most frequent occurring
at 10p (6 out of 21, 29%), 10q (5 out of 21, 24%) and 2q, 3p and 11q
Table 1 Recurrent aberrations in VIN and VSCC
Frequencya
Chromosome
Copy number
change VIN (n¼ 21) VSCC (n¼ 6)
1p Gain 13 (62%) 6 (100%)
1q Gain 10 (48%) 3 (50%)
2q Deletion 4 (19%) 2 (33%)
3p Deletion 4 (19%) 2 (33%)
6p UPD 5 (24%) 0
8p Gain 4 (19%) 2 (33%)
8q Gain 5 (24%) 3 (50%)
9p Gain 5 (24%) 2 (33%)
9q Gain 8 (38%) 3 (50%)
10p Deletion 6 (29%) 1 (17%)
10q Deletion 5 (24%) 1 (17%)
14q Deletion 1 (5%) 2 (33%)
16p Gain 7 (33%) 0
16q Gain 6 (29%) 0
19 Gain 13 (62%) 3 (50%)
20p Gain 14 (66%) 4 (67%)
20q Gain 14 (66%) 4 (67%)
22q Gain 9 (43%) 2 (33%)
Xp Deletion 1 (5%) 2 (33%)
Xp Gain 8 (38%) 1 (17%)
Xq Gain 7 (33%) 1 (17%)
Abbreviations: UPD¼ uniparental disomy or copy-neutral loss of heterozygosity;
VIN¼ vulval intraepithelial neoplasia; VSCC¼ vulval squamous cell carcinoma.
aEvents are only listed if they occurred in 20% or more of one sample group.
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(all 4 out of 21, 19% samples). Comparison of SNP genotypes in
lesional and paired normal samples revealed that 5 of 21 samples
(24%) displayed extensive loss of heterozygosity (LOH) at 6p in the
absence of copy number change. In three cases this copy-neutral
LOH, also known as uniparental disomy (UPD), involved the distal
region from 6pter-6p21.3 (Figure 2). The remaining two samples
showed UPD across the whole of chromosome 6. In VSCC, gains
remained the most frequent events, with all six samples showing
chr1 chr2 chr3 chr4 chr5 chr6
chr7 chr8 chr9 chr10 chr11 chr12
chr13 chr14 chr15 chr16 chr17 chr18
chr19 chr20 chr21 chr22 chrX chrY
Figure 1 Ideogram summarising allelic imbalance in high-grade VIN (light coloured lines) and VSCC (dark coloured lines). Loss of heterozygosity events
are indicated to the left of chromosomes with deletion shown in green and uniparental disomy in blue and gains are indicated to the right in red.
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1p gain (Table 1, Figure 1). Gain of whole chromosome 20 was
observed in four of six samples (67%) and gains at 1q, 8q, 9q and
whole chromosome 19 all occurred in three samples (50%).
Recurrent losses occurred at 2q, 3p, 14q and Xp, all in two of six
(33%) samples.
Most frequent recurrent aberration in CxSCC
was not detected in vulval neoplasia
To examine whether the genetic alterations observed here were
shared by other HPV-associated genital neoplasia, we used the
same software platform to analyse previously published data
from a series of 70 cervical carcinomas that had been subjected to
an identical microarray analysis protocol (Scotto et al, 2008b).
Final analysis was restricted to 53 HPV-positive CxSCC with high
call rates, including 10 tumours classified as Stage IA/IB according
to Federation of Gynaecology and Obstetrics cervical carcinoma
staging criteria (defined as carcinoma confined to the cervix). Gain
at 5p, which had been identified as the most frequent recurrent
change in the series of 70 CxSCC (Scotto et al, 2008b), was
observed in 58% (31 out of 53) of the re-analysed cervical tumours
compared with none of the 27 vulval neoplasia samples. Statistical
analysis revealed that this aberration was significantly more
frequent in CxSCC than VSCC, P-value¼ 0.0083. The difference
between the two groups did not reflect the earlier tumour stage of
the VSCC series because this event occurred at comparable
frequency in Stage I cervical tumours (50%; Table 2). Other
differences between the two tumour groups were not significant at
the 5% level after adjustment for multiple testing.
DISCUSSION
This study is the first to investigate the genome-wide genetic
changes in HPV-associated VIN and VSCC using high-resolution
SNP array analysis. In a series of 27 VIN/VSCC samples with
matched normal tissue, we have shown gains to be the most
frequent chromosomal aberrations in both VIN and VSCC. The
most common recurrent aberrations were gains, at 1p and 20 in
particular. Some recurrent deletions were also observed, most
frequently at 2q, 3p and 10. Copy-neutral LOH at 6p was a
recurrent event in VIN. Despite our use of high-resolution SNP
analysis, gross chromosomal aberrations comprised the majority
of the recurrent events, with a few exceptions such as 3p and14q
microdeletions, each observed in single VSCC samples (Figure 1).
None of the 27 samples displayed gain at 5p, the most frequent
genetic alteration previously reported in a series of CxSCC
analysed using an identical protocol.
Comparison with previous studies on vulval neoplasia
This study is the first to use a high-resolution array-based
technique to analyse the genetic alterations associated with
hrHPV-positive VIN and VSCC. Indeed, few studies have
previously examined the genetic changes associated with high-
grade VIN using lower resolution techniques. One investigation
(Rosenthal et al, 2001) reported that, of 6 loci (3p, 4q, 5p, 9p, 11p
and 17p) examined for LOH using microsatellite marker analysis,
3p was the most frequently affected with LOH in 8 of 28 (29%)
informative HPV-positive VIN3 samples, comparable to this study.
Elsewhere, metaphase CGH was used to analyse the genetic events
VIN11
VIN15
VIN17
Figure 2 Copy-neutral LOH at chromosome 6pter-6p21.3 in three high-grade VIN samples. Upper panels indicate lesional/non-lesional copy number
ratios plotted on a log2 scale according to chromosomal position. Upper line represents log2(2) and lower line represents log2(0.5). Lower panels depict a
comparison of SNP genotypes in VIN and paired normal samples. Single-nucleotide polymorphism loci shown in green indicate calls conserved between the
two samples, loci shown in red immediately above indicate LOH in the VIN3 sample and loci shown in red on the top row indicate SNPs not called in the
VIN3 sample. Localised areas of low call rates may imply LOH in a subpopulation of cells. Note that sample VIN 15 additionally exhibits LOH accompanied
by loss of copy number (deletion) at 6q24.3-6q25.3.
Table 2 Comparison of aberrations in VSCC and CxSCC
Event VSCC All CxSCCa Stage Ib CxSCC
Gain at 1p 6/6 (100%) 24/53 (45%) 4/10 (40%)
Gain at 1q 3/6 (50%) 29/53 (55%) 5/10 (50%)
Loss at 2q 2/6 (33%) 22/53 (43%) 3/10 (30%)
Loss at 3p 2/6 (33%) 34/53 (64%) 4/10 (40%)
Gain at 3q 1/6 (17%) 37/53 (70%) 6/10 (60%)
Loss at 4p 1/6 (17%) 26/53 (49%) 6/10 (60%)
Loss at 4q 0/6 24/53 (45%) 7/10 (70%)
Gain at 5p 0/6 31/53 (58%) 5/10 (50%)
Loss at 5q 1/6 (17%) 17/53 (32%) 2/10 (20%)
Gain at 6p 0/6 13/53 (25%) 3/10 (30%)
Gain at 7q 3/6 (50%) 10/53 (19%) 2/10 (20%)
Gain at 8p 2/6 (33%) 16/53 (30%) 2/10 (20%)
Gain at 8q 3/6 (50%) 23/53 (43%) 2/10 (20%)
Loss at 9p 0/6 10/53 (19%) 2/10 (20%)
Gain at 9q 3/6 (50%) 14/53 (26%) 1/10 (10%)
Loss at 11q 1/6 (17%) 24/53 (45%) 3/10 (30%)
Loss at 13q 1/6 (17%) 23/53 (43%) 2/10 (20%)
Loss at 14q 2/6 (33%) 2/53 (4%) 0/10 (0%)
Gain at 15q 0/6 16/53 (30%) 1/10 (10%)
Gain at 19q 3/6 (50%) 27/53 (50%) 6/10 (60%)
Gain at 20q 4/6 (67%) 22/53 (42%) 3/10 (30%)
Gain at 22q 2/6 (33%) 13/53 (25%) 2/10 (20%)
aReanalysed data from a previous study on cervical carcinomas (Scotto et al, 2008b).
bAccording to FIGO criteria, Stage I CxSCC is carcinoma restricted to the cervix.
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in nine HPV-positive VIN3 samples (Bryndorf et al, 2004). In line
with this study, gains of whole chromosomes 1 and 20 were the
most frequent aberrations observed in six (67%) and five
(56%) of nine VIN3 samples, respectively. In contrast, gains at
chromosome 19 were not detected; however, metaphase CGH has
been shown to be unreliable for analysis of chromosome 19
aberrations (Kallioniemi et al, 1994).
The genetic alterations associated with hrHPV-positive
VSCC have been analysed previously in several studies using
various lower resolution techniques (summarised in Supple-
mentary Table 2). Differences exist between these earlier
investigations both in the nature of the samples (formalin-fixed
paraffin embedded vs fresh frozen) and the methodologies
used (microsatellite marker analysis that solely detects LOH vs
metaphase CGH that has greater sensitivity for gain events).
Nevertheless, all seven previous studies identified loss at 3p as
an important event, occurring in 14% (1 out of 7) to 67% (4 out of 7)
of samples, and recurrent gain of 8q was observed in all five CGH
studies in 20% (2 out of 10) to 67% (4 out of 6) samples. Direct
comparisons with our data are limited by methodological
differences; however, both of these findings were consistent with
our data. Some dissimilarities were apparent, in particular the
lower frequency of gains reported elsewhere at chromosomes 1, 19
and 20. One explanation for these discrepancies may be the
comparatively low overall level of the gains; in our samples the
copy number ratios of these gains were often considerably lower
than 1.5, suggesting that the frequency of these events may have
been underestimated elsewhere had a higher cutoff value been
used. Alternatively, because the low copy number ratio implied
that the gains were present in only a subset of tumour cells and the
samples examined here were early stage (Stage IA/B) cancers, it is
possible that this subpopulation might decrease during VSCC
progression. This would be consistent with data from one previous
study showing a high frequency of chromosome 1 and 20 gains
in VIN3 but not VSCC samples (Bryndorf et al, 2004). The
fact that another investigation (Huang et al, 2005) observed gains
at chromosomes 1 and 20 in only 17% of metastatic tumours
provides further support for this theory. Although the remaining
studies provided no information on tumour stage, the authors
reported frequent recurrent gains at 3q and 5p, which have been
shown to correlate with pathological staging of SCC (Oga et al,
2001; Yen et al, 2001; Noguchi et al, 2003; Klussmann et al, 2009);
hence, it seems likely that many of these samples were also late
stage tumours. Finally, it should be noted that two of the CGH
studies included in the comparison (Jee et al, 2001; Micci et al,
2003) did not investigate the HPV status of the VSCC analysed;
hence, it remains unclear whether their results are relevant to
HPV-associated vulval neoplasia.
Vulval and CxSCC may be associated with different genetic
alterations
Our data suggest that vulval and cervical tumours may exhibit
different patterns of chromosomal aberrations. Specifically,
reanalysis of previously published CxSCC data revealed frequent
recurrent gain at 5p. Other studies have reported a similar finding
in early stage cervical tumours. For example, Wilting et al (2006)
identified recurrent 5p gain in 33% (3 out of 9) non-metastatic
CxSCC and Scotto et al (2008b) reported that 26% (5 out of 19) of
high-grade CIN samples showed gain at 5p. In contrast, none of the
series of 27 high-grade VIN and VSCC in this study displayed this
aberration. Statistical analysis revealed a significant difference
between CxSCC and VSCC samples with respect to 5p gain,
although any definite conclusions must be limited by the small
number of VSCC examined. After controlling for multiple testing,
the other differences observed between the two tumour groups
were not significant. However, it would be of interest to investigate
some of these differences further in a larger series of vulval
samples. For example, 3q gain was detected in 17% (1 out of 6)
VSCC compared with 70% (37 out of 53) of the CxSCC series
analysed concomitantly (including 60%, 6 out of 10 of the Stage I
tumours) and 100% (9 out of 9) of the Stage I and II cervical
tumours investigated by Wilting et al (2006). Furthermore,
frequent recurrent gain of 3q has been reported in cervical
neoplasia before the acquisition of the invasive phenotype:
Kirchhoff et al (1999) and Umayahara et al (2002) identified 3q
gain in 35% (6 out of 17) and 61% (11 out of 18), respectively, of
CIN3 samples compared with 14% (3 out of 21) high-grade VIN in
this study. These combined data suggest that chromosomal
aberrations characteristic of advanced SCC at several sites,
including hrHPV-associated cancers such as tonsillar SCC (Oga
et al, 2001; Yen et al, 2001; Dahlgren et al, 2003; Noguchi et al,
2003; Klussmann et al, 2009), commonly appear at an early stage of
cervical transformation.
It is well established that the incidence of cervical carcinoma is
5- to 10-fold greater than that of other lower genital tract cancers
and peaks at least 10 years earlier (Watson et al, 2008). HPV
infections are commonly detected throughout the region (Hording
et al, 1996), implying that cervical epithelium may be more
susceptible to transformation than other anogenital epithelia. The
cervix bears a unique anatomical feature, the transformation zone,
where squamous metaplasia occurs as a normal physiological
phenomenon. It is this area that is particularly susceptible to HPV
infection and where both infection and CIN begin. The reasons for
this remain unknown. This may be because the cellular micro-
environment of replicating non-maturing reserve cells or unique
cell-surface receptors on this cell population favour HPV infection
(Crum, 2000). The prevalence of HPV-18 infection is higher in
cervical than in other anogenital SCC (De Vuyst et al, 2009), and it
has been speculated that HPV-18 infection may be more aggressive
clinically (Bulk et al, 2007). However, differences in type-specific
prevalence are not sufficiently great to account for the disparity in
cancer incidence. Another possible explanation is that the
susceptibility to hrHPV-mediated transformation of the various
anogenital epithelia may in part reflect their immune or hormonal
microenvironment. It has recently been found that the clinical
outcome of preinvasive cervical lesions can be accurately predicted
by the physical status of the hrHPV genome (integrated vs
episomal) in conjunction with viral load (Wanram et al, 2009). The
transition from low-grade dysplastic lesion harbouring episomal
genomes to late-stage invasive carcinoma containing only
integrated copies has been shown to occur by an intermediate
step in which episomal and integrated genomes co-exist (Pett et al,
2004). Cells harbouring both genome types were characterised by
copy number imbalances that predominantly comprised whole
chromosome gains or losses, similar to the genetic events observed
in vulval neoplasia in this study. In contrast, cells containing HPV
integrant alone displayed frequent structural as well as numerical
chromosomal instability, with recurrent aberrations including gain
at 3q and 5p, mirroring those identified in the cervical tumours
analysed here as well as in high-grade CIN (Scotto et al, 2008b).
During the intermediate stage, integrants are subject to transcrip-
tional repression by the episomal genomes (Dall et al, 2008).
Selective advantage has been found to be insufficient for the
progression of the integrant-bearing cell (Pett et al, 2006); rather
there appears to be a requirement for episomal clearance, which
can be hastened by treatment with various immunomodulators
including type I interferon (Herdman et al, 2006). The physical
status of the hrHPV genome in vulval neoplasia remains unclear.
Data suggest that HPV integrants are present in a lower proportion
of high-grade VIN than CIN (Hudelist et al, 2004; Hillemanns and
Wang, 2006). The presence in VSCC of both integrated and
episomal forms has been shown (Ueda et al, 2004), although
analysis was restricted to a single sample. A larger study identified
HPV integrants in the majority of VSCC examined (van de
Nieuwenhof et al, 2009); however, the possibility of co-existent
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viral episomes was not excluded. Further work is clearly required
to examine this hypothesis.
HPV-associated VSCC display HPV-specific aberrations
Previous studies have reported significant genetic differences
between hrHPV-associated and hrHPV-independent SCC at a range
of anatomical sites, including the oral cavity, oropharynx and cervix
(Dahlgren et al, 2003; Braakhuis et al, 2004; Smeets et al, 2006;
Klussmann et al, 2009; Wilting et al, 2009). The alterations identified
as specific for hrHPV-independent tumours, namely recurrent
losses at 5q and 9p and gains at 7q and 11q, were not observed in
our VSCC series. Conversely, recurrent gain at chromosome 20,
observed in 67% (4 out of 6) VSCC, was found to be a specific
marker of HPV-associated cancer. All five earlier studies also
reported that hrHPV-positive SCC were characterised by a lower
level of chromosomal aberrations overall. Our laboratory has
performed preliminary analysis (data not shown) on three HPV-
independent VSCC, categorised thus because tumours developed in
a background of lichen sclerosus and/or differentiated VIN and
tested negative for hrHPV DNA. These data suggest that the
significant genetic differences between hrHPV-positive and hrHPV-
negative tumours observed at other sites may be mirrored in the
vulva. The most marked difference was the finding of 9p loss in all
three HPV-independent tumours. In addition, allelic imbalance was
observed at a mean number of 10 chromosomes, compared with 6.5
in the HPV-associated VSCC. In contrast to these data, an earlier
study from our laboratory (Purdie et al, 2009) examining the
genetics of cutaneous SCC found no significant differences between
HPV-positive and HPV-negative tumours. However, it must be
noted that skin cancers are overwhelmingly associated with HPV
from the b rather than a genus. The most common recurrent
chromosomal aberration identified in cutaneous SCC was LOH at
9p, with similar frequencies in HPV-positive and HPV-negative SCC
(32 out of 43, 74% and 13 out of 17, 76% respectively), whereas gain
at chromosome 20 was observed at much lower frequency in 16% (7
out of 43) and 18% (3 out of 17) of HPV-positive and HPV-negative
tumours, respectively. These combined data suggest that HPV from
the b and a genera are associated with distinct patterns of
chromosomal aberrations.
Possible candidate genes targeted by genetic alterations
Despite considerable methodological differences, combined data
from the current and previous investigations suggest a character-
istic pattern of genetic changes within VSCC. In particular,
deletion at 3p was reported as a frequent recurrent event in all
studies. This aberration is likely to target fragile histidine triad
(FHIT), a recognised tumour suppressor gene known to be
inactivated in other SCC (Yoshino et al, 2000; Lee et al, 2006;
Purdie et al, 2009). Indeed, one of the VSCC samples exhibited a
microdeletion restricted to the FHIT locus at 3p14.2. FHIT is located
at the fragile site FRA3B, which has been identified as an integration
hotspot for HPV (Huang et al, 2005), although FHIT also appears
to be targeted during HPV-independent carcinogenesis. Gain
at 8q, resulting in amplification of the oncogene c-Myc (Issing
et al, 1993), was also consistently identified, as was gain at
chromosome 20, a specific marker of HPV-associated cancer that
has been reported to result in elevated mRNA levels of the de novo
DNA methyltransferase DNMT3B at 20q (Wilting et al, 2006).
In vitro studies (Savelieva et al, 1997; Klingelhutz et al, 2005) have
shown that gain at 20q is an early event in hrHPV-mediated
immortalisation of epithelial cells, suggesting that increased
DNMT3B expression may contribute to the sequential tumour
suppressor gene promoter hypermethylation that has been
identified during HPV-induced transformation (Henken et al,
2007). Overall, the most frequent event across our series was gain
at 1p, shown elsewhere to correlate with increased expression of
the JUN protooncogene (Taniguchi et al, 2007). Gain at 3q, a
marker of late stage HPV-associated cancer, was less frequently
observed in the VSCC series. This aberration has been shown to
result in the amplification of hTERC, the RNA component of
human telomerase (Heselmeyer-Haddad et al, 2003), thereby
complementing the activity of the hrHPV E6 oncoprotein that
transcriptionally activates hTERT, the catalytic subunit of telomer-
ase (Veldman et al, 2001). Uniparental disomy at 6p was the only
recurrent copy-neutral LOH event identified in the series.
Although this aberration was restricted to VIN samples, VSCC
numbers were too small to determine whether this represented a
genuine difference between preinvasive and invasive lesions. In
cervical neoplasia, LOH at 6p is frequent in both high-grade CIN
and CxSCC (Chatterjee et al, 2001; Kloth et al, 2007). Evidence
suggests that HLA class I genes are the target of this aberration
(Koopman et al, 2000), thereby permitting tumours to escape
immune surveillance.
In summary, we have used high-resolution SNP microarray
analysis to investigate genome-wide allelic imbalance in hrHPV-
associated vulval neoplasia. Across the spectrum, gains of
chromosomal material were more frequent than losses. Despite
shared HPV status and regional proximity, our data suggest that
vulval and cervical tumours may differ in their pattern of
associated genetic alterations. A better understanding of any
differences is likely to provide insight into mechanisms of HPV-
associated epithelial carcinogenesis and may prove important in
future studies of diagnostic, predictive and therapeutic biomarkers
relevant to VSCC treatment and prevention.
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